A CFD Model of Mixing in a Microfludic Device for Space Medicine Technology

The DNA Medicine Institute (DMI) is currently developing a device to be used for blood analysis to satisfy the unique requirements of space medicine applications. A key component of that device is the micromixer, which will ensure mixing and dilution of reagents utilized for detection assays. As part of the device design process, the micromixer was modeled, and the mixing characteristics were analyzed and compared to experimental data. The experimental data was based on a top-view of the system and, lacking data throughout the fluid domain, could not provide the insight into the mixing process that modeling could readily provide. COMSOL, a Finite Element Method (FEM) package, was used to model the mixer. The mixer design is essentially a spiral channel and relies on centrifugal effects, or Dean flow forces that arise from flows in curved channels, to enhance mixing. A computational model of DMI\u27s spiral mixer was analyzed and compared to experimental data for flow ranging in Reynolds number between 8 and 90. The Dean number range was between 0 and 25. The fluids modeled were miscible and Newtonian. It was observed that at Reynolds number less than 12 (De 11), convective forces dominated. In an intermediate range, Reynolds numbers between 12 and 30 (De 2 - 11), mixing appeared to be enhanced as both diffusion and convection aided the mixing. Due to the rotational nature of the flow, this was not readily apparent from the experimental data. The model is a good tool to optimize design choices since the numerical data can be used to quantify mixing characteristics throughout the entire mixer volume, thereby providing a better insight into mixing performanc

IVGEN

The Exploration Medical Capabilities Element of NASA's Human Research Program chartered the IV fluid GENeration (IVGEN) project at the NASA Glenn Research Center to develop a system that could produce IV fluid in a microgravity environment meeting USP standards. NASA's flight surgeons have identified medical conditions likely to arise during exploration missions of various length and distance from the earth. Adequately treating some of those conditions will require the ability to utilize Intravenous (IV) therapy to either serve as a method for delivering pharmaceuticals that can only be administered via that route, or to hydrate patients that are unable to hydrate themselves. Given that need, NASA currently maintains a reserve of IV fluid on ISS sufficient to treat an astronaut until they can be returned to earth, which is generally within 24 hours. Because such a rapid return will not be an designed to produce United States Pharmacopeia ( USP) grade IV fluid in a reduced gravity p option for missions extending beyond low earth orbit, NASA must either fly as many as 100 liters of IV fluid, with a total mass of 100 Kg, or provide systems that can use vehicle resources to produce such fluid if it is needed. The IVGEN hardware, a compact water purification and mixing system, was environment using available resources

Intravenous Fluid Generation System

The ability to stabilize and treat patients on exploration missions will depend on access to needed consumables. Intravenous (IV) fluids have been identified as required consumables. A review of the Space Medicine Exploration Medical Condition List (SMEMCL) lists over 400 medical conditions that could present and require treatment during ISS missions. The Intravenous Fluid Generation System (IVGEN) technology provides the scalable capability to generate IV fluids from indigenous water supplies. It meets USP (U.S. Pharmacopeia) standards. This capability was performed using potable water from the ISS; water from more extreme environments would need preconditioning. The key advantage is the ability to filter mass and volume, providing the equivalent amount of IV fluid: this is critical for remote operations or resource- poor environments. The IVGEN technology purifies drinking water, mixes it with salt, and transfers it to a suitable bag to deliver a sterile normal saline solution. Operational constraints such as mass limitations and lack of refrigeration may limit the type and volume of such fluids that can be carried onboard the spacecraft. In addition, most medical fluids have a shelf life that is shorter than some mission durations. Consequently, the objective of the IVGEN experiment was to develop, design, and validate the necessary methodology to purify spacecraft potable water into a normal saline solution, thus reducing the amount of IV fluids that are included in the launch manifest. As currently conceived, an IVGEN system for a space exploration mission would consist of an accumulator, a purifier, a mixing assembly, a salt bag, and a sterile bag. The accumulator is used to transfer a measured amount of drinking water from the spacecraft to the purifier. The purifier uses filters to separate any air bubbles that may have gotten trapped during the drinking water transfer from flowing through a high-quality deionizing cartridge that removes the impurities in the water before entering the salt bag and mixing with the salt to create a normal saline solution

Planetary Protection Concerns During Pre-Launch Radioisotope Power System Final Integration Activities

The Advanced Stirling Radioisotope Generator (ASRG) is a next-generation radioisotope-based power system that is currently being developed as an alternative to the Multi-Mission Radioisotope Thermoelectric Generator (MMRTG). Power sources such as these may be needed for proposed missions to solar system planets and bodies that have challenging Planetary Protection (PP) requirements (e.g. Mars, Europa, Enceladus) that may support NASA s search for life, remnants of past life, and the precursors of life. One concern is that the heat from the ASRG could potentially create a region in which liquid water may occur. As advised by the NASA Planetary Protection Officer, when deploying an ASRG to Mars, the current COSPAR/NASA PP policy should be followed for Category IVc mission. Thus, sterilization processing of the ASRG to achieve bioburden reduction would be essential to meet the Planetary Protection requirements. Due to thermal constraints and associated low temperature limits of elements of the ASRG, vapor hydrogen peroxide (VHP) was suggested as a candidate alternative sterilization process to complement dry heat microbial reduction (DHMR) for the assembled ASRG. The following proposed sterilization plan for the ASRG anticipates a mission Category IVc level of cleanliness. This plan provides a scenario in which VHP is used as the final sterilization process. Keywords: Advanced Stirling Radioisotope Generator (ASRG), Planetary Protection (PP), Vapor hydrogen peroxide (VHP) sterilization

Final Report for Intravenous Fluid Generation (IVGEN) Spaceflight Experiment

NASA designed and operated the Intravenous Fluid Generation (IVGEN) experiment onboard the International Space Station (ISS), Increment 23/24, during May 2010. This hardware was a demonstration experiment to generate intravenous (IV) fluid from ISS Water Processing Assembly (WPA) potable water using a water purification technique and pharmaceutical mixing system. The IVGEN experiment utilizes a deionizing resin bed to remove contaminants from feedstock water to a purity level that meets the standards of the United States Pharmacopeia (USP), the governing body for pharmaceuticals in the United States. The water was then introduced into an IV bag where the fluid was mixed with USP-grade crystalline salt to produce USP normal saline (NS). Inline conductivity sensors quantified the feedstock water quality, output water purity, and NS mixing uniformity. Six 1.5-L bags of purified water were produced. Two of these bags were mixed with sodium chloride to make 0.9 percent NS solution. These two bags were returned to Earth to test for compliance with USP requirements. On-orbit results indicated that all of the experimental success criteria were met with the exception of the salt concentration. Problems with a large air bubble in the first bag of purified water resulted in a slightly concentrated saline solution of 117 percent of the target value of 0.9 g/L. The second bag had an inadequate amount of salt premeasured into the mixing bag resulting in a slightly deficient salt concentration of 93.8 percent of the target value. The USP permits a range from 95 to 105 percent of the target value. The testing plans for improvements for an operational system are also presented

Best Practices for Educational Interpreters in South Carolina

The purpose of this reference is to provide districts, charter schools, and state operated programs with best practices for working with educational interpreters including, but not limited to, roles and responsibilities, code of professional conduct, and suggested credentialing. It is not required by regulation but is simply the most up-to-date recommendation from the field

By Different Cellular Mechanisms, Lymphatic Vessels Sprout by Endothelial Cell Recruitment Whereas Blood Vessels Grow by Vascular Expansion

The development of effective vascular therapies requires the understanding of all modes of vessel formation contributing to vasculogenesis, angiogenesis (here termed hemangiogenesis) and lymphangiogenesis. We show that lymphangiogenesis proceeds by blind-ended vessel sprouting via recruitment of isolated endothelial progenitor cells to the tips of growing vessels, whereas hemangiogenesis occurs by non-sprouting vessel expansion from the capillary network, during middevelopment in the quail chorioallantoic membrane (CAM). Blood vessels expanded out of capillaries that displayed transient expression of alpha smooth muscle actin (alphaSMA), accompanied by mural recruitment of migratory progenitor cells expressing SMA. Lymphatics and blood vessels were identified by confocal/fluorescence microscopy of vascular endothelial growth factor (VEGF) receptors VEGFR-1 and VEGFR-2, alphaSMA (expressed on CAM blood vessels but not on lymphatics), homeobox transcription factor Prox-1 (specific to CAM lymphatic endothelium), and the quail hematopoetic/vascular marker, QH-1. Expression of VEGFR-1 was highly restricted to blood vessels (primarily capillaries). VEGFR-2 was expressed intensely in isolated hematopoietic cells, lymphatic vessels and moderately in blood vessels. Prox-1 was absent from endothelial progenitor cells prior to lymphatic recruitment. Although vascular endothelial growth factor-165 (VEGF(sub 165)) is a key regulator of numerous cellular processes in hemangiogenesis and vasculogenesis, the role of VEGF(sub 165) in lymphangiogenesis is less clear. Exogenous VEGF(sub 165) increased blood vessel density without changing endogenous modes of vascular/lymphatic vessel formation or marker expression patterns. However, VEGF(sub 165) did increase the frequency of blood vascular anastomoses and strongly induced the antimaturational dissociation of lymphatics from blood vessels, with frequent formation of homogeneous lymphatic networks

Microvascular Branching as a Determinant of Blood Flow by Intravital Particle Imaging Velocimetry

The effects of microvascular branching on blood flow were investigated in vivo by microscopic particle imaging velocimetry (micro-PIV). We use micro-PIV to measure blood flow by tracking red blood cells (RBC) as the moving particles. Velocity flow fields, including flow pulsatility, were analyzed for the first four branching orders of capillaries, postcapillary venules and small veins of the microvascular network within the developing avian yolksac at embryonic day 5 (E5). Increasing volumetric flowrates were obtained from parabolic laminar flow profiles as a function of increasing vessel diameter and branching order. Maximum flow velocities increased approximately twenty-fold as the function of increasing vessel diameter and branching order compared to flow velocities of 100 - 150 micron/sec in the capillaries. Results from our study will be useful for the increased understanding of blood flow within anastomotic, heterogeneous microvascular networks

Intravenous Fluid Generation (IVGEN) for Exploration Missions

No abstract availabl

Effectiveness guidance document (EGD) for acupuncture research - a consensus document for conducting trials

Abstract Background There is a need for more Comparative Effectiveness Research (CER) to strengthen the evidence base for clinical and policy decision-making. Effectiveness Guidance Documents (EGD) are targeted to clinical researchers. The aim of this EGD is to provide specific recommendations for the design of prospective acupuncture studies to support optimal use of resources for generating evidence that will inform stakeholder decision-making. Methods Document development based on multiple systematic consensus procedures (written Delphi rounds, interactive consensus workshop, international expert review). To balance aspects of internal and external validity, multiple stakeholders including patients, clinicians and payers were involved. Results Recommendations focused mainly on randomized studies and were developed for the following areas: overall research strategy, treatment protocol, expertise and setting, outcomes, study design and statistical analyses, economic evaluation, and publication. Conclusion The present EGD, based on an international consensus developed with multiple stakeholder involvement, provides the first systematic methodological guidance for future CER on acupuncture.http://deepblue.lib.umich.edu/bitstream/2027.42/112870/1/12906_2012_Article_1127.pd